BACKGROUND: The Thrombolysis in Myocardial Infarction (TIMI) risk score estimates mortality for patients with ST-elevation myocardial infarction (STEMI). This study aimed to investigate whether biomarkers reflecting the neurohormonal response (pro-atrial natriuretic peptide (proANP), mid-regional pro-adrenomedullin (MR-proADM), and copeptin), inflammation (suppression of tumorigenicity 2 (ST2), C-reactive protein (CRP), and leukocytes), and troponin add prognostic value to the TIMI risk score. METHODS: This sub-study of the prospective PREDICT cohort included 1700 non-comatose and non-cardiogenic shock STEMI patients upon admission. Blood samples were collected before coronary angiography. Biomarker quartiles (Q4vsQ1-3) association with 30-day mortality were examined using Cox proportional hazard models. RESULTS: High levels of all biomarkers were associated with 30-day mortality independently of TIMI risk score, hazard ratio (HR) CONCLUSION: TIMI risk score and all the biomarkers added prognostic values of 30-day mortality. The strongest predictor of 30-day mortality was observed for MR-proADM alone.